AUS
NZ
UK
CA
USA
IND
Highlights
- Healthcare, pharmaceuticals, biotechnology and regulated wellness markets continue shaping Canada’s healthcare sector.
- Curaleaf, Bausch Health, Green Thumb Industries, Bright Minds Biosciences and Knight Therapeutics represent diverse exposure across cannabis healthcare, specialty pharma and biotech research.
- Product innovation, regulatory developments and global treatment demand remain long-term themes supporting the sector.
Canada’s healthcare sector continues evolving as pharmaceuticals, biotechnology, wellness products and specialty treatments become increasingly important across global markets. Companies across the sector are focusing on product development, treatment access, regulated healthcare markets and international expansion. Against this backdrop, the S&P/TSX Composite Index continues reflecting broader market trends, while Healthcare Stocks remain closely watched as medical innovation, patient demand and regulatory progress continue shaping the industry.
1. Curaleaf Holdings Inc. (TSX:CURA)
Curaleaf Holdings is a cannabis-focused healthcare and wellness company with operations across regulated markets.
The company continues developing cannabis-based products for medical and adult-use consumers while expanding its retail and branded product presence. Its focus on regulated cannabis markets keeps it linked to the broader healthcare and wellness industry.
2. Bausch Health Companies Inc. (TSX:BHC)
Bausch Health Companies is a global specialty pharmaceutical company with products across gastroenterology, dermatology, eye health and other therapeutic areas.
The company continues focusing on branded pharmaceuticals, treatment access and operational improvement. Its diversified product portfolio provides exposure to multiple healthcare categories across international markets.
3. Green Thumb Industries Inc. (TSX:GTII)
Green Thumb Industries operates in the regulated cannabis sector, producing and distributing cannabis-based consumer and healthcare products.
The company’s product portfolio includes branded cannabis offerings across medical and adult-use markets. As regulated cannabis continues developing across North America, Green Thumb remains positioned within a specialised healthcare-linked consumer category.
4. Bright Minds Biosciences Inc. (TSX:DRUG)
Bright Minds Biosciences is a biotechnology company focused on developing next-generation therapies targeting neurological and psychiatric conditions.
The company’s research pipeline is centred on innovative compounds designed to address areas of unmet medical need. Its biotechnology focus places it within the higher-risk, research-driven side of Canada’s healthcare market.
5. Knight Therapeutics Inc. (TSX:GUD)
Knight Therapeutics is a specialty pharmaceutical company focused on acquiring, licensing and commercialising pharmaceutical products across Canada and international markets.
The company continues building its portfolio through partnerships, product launches and targeted healthcare opportunities. Its model supports exposure to specialty medicines without relying solely on early-stage drug discovery.
Why TSX healthcare stocks remain important
Several structural trends continue supporting healthcare companies:
- Rising healthcare demand
- Pharmaceutical product innovation
- Biotechnology research
- Regulated cannabis healthcare markets
- Specialty medicine expansion
- Mental health treatment development
- Global patient access
These themes continue supporting interest across pharmaceutical companies, biotechnology developers and healthcare-linked wellness businesses as demand for medical solutions continues growing.
Canada’s healthcare sector remains diverse, covering specialty pharmaceuticals, cannabis healthcare, biotechnology and treatment innovation. Curaleaf Holdings Inc. (TSX:CURA), Bausch Health Companies Inc. (TSX:BHC), Green Thumb Industries Inc. (TSX:GTII), Bright Minds Biosciences Inc. (TSX:DRUG) and Knight Therapeutics Inc. (TSX:GUD) each represent different areas of the healthcare value chain. As medical innovation, regulatory progress and patient demand remain key sector priorities, these companies continue highlighting the depth of Canada’s healthcare market.
